Avanti Biosciences Inc

Avanti Biosciences is a biopharmaceutical company headquartered at Johnson & Johnson Innovation – JLABS in San Diego, advancing an oral precision kinase inhibitor for idiopathic pulmonary fibrosis (IPF), a devastating lung disease affecting more than 150,000 adults in the United States.

Every approved therapy for IPF slows the decline. None of them reverses it. Our lead asset, ABI-171, is designed to reverse it.

Our lead asset, ABI-171, is IND-ready with FDA Orphan Drug Designation, supported by a comprehensive preclinical package including human fibroblast mechanistic validation, functional in vivo endpoints, and head-to-head comparison with current standard of care. Phase 1 initiation targeted H2 2026.

Our scientific founders bring globally recognized expertise in fibrotic disease biology, backed by over $6M in NIH funding including a recent NIDDK SBIR grant in collaboration with Ohio State University.

At a Glance

FDA Pre-IND meeting completed (March 2026)
IND-ready precision kinase inhibitor program in Idiopathic Pulmonary Fibrosis (IPF) and NASH-Associated Liver Fibrosis
FDA Orphan Drug Designation
$6M+ NIH non-dilutive funding including NIDDK SBIR grant
Phase 1 initiation targeted H2 2026

At a Glance

FDA Pre-IND meeting completed (March 2026)

IND-ready precision kinase inhibitor program in Idiopathic Pulmonary Fibrosis (IPF) and NASH-Associated Liver Fibrosis

FDA Orphan Drug Designation

$6M+ NIH non-dilutive funding including NIDDK SBIR grant

Phase 1 initiation targeted H2 2026